Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

In A Rare Disorder, A Familiar Protein Disrupts Gene Function
As reported this week in the open-access journal PLoS Biology, an
buy viagra
Low Blood Glucose Levels Do Not Explain Excess Deaths In Accord Trial
Low blood glucose levels do not explain the excess deaths seen in the intensive control group of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, according to a report presented here today at the American Diabetes Association"s 69th Scientific Sessions.
News of the day
Covidien Announces Milestone Placement In Remote Respiratory Monitoring
Covidien (NYSE: COV), a leading global provider of healthcare products, has announced a key milestone in the continued growth and use of the OxiNet™ III remote respiratory monitoring system in U.S. hospitals. With the recent system installation at the Mayo Clinic campus in Jacksonville, FL, the Nellcor™ OxiNet III system currently monitors 10,000 beds and is integrated into more than 450 U.S. hospitals, including the Mayo Clinic campus in Rochester, MN, M.D. Anderson Cancer Center (Houston, TX), St. Anthony Central Hospital (Denver, CO) and Sumner Regional Medical Center (Gallatin, TN). The OxiNet III remote monitoring system enhances the safety of patients throughout the hospital, enabling continuous monitoring of patients" oxygen saturation levels via the trusted Nellcor OxiMax™ product platform, even when the clinician is not at the bedside.
Nutrition

UPMC Cardiovascular Institute Recruiting For Severe Coronary Heart Disease Study

The UPMC Cardiovascular Institute currently is enrolling participants for a Phase 2 clinical trial to examine whether administering a naturally occurring protein improves blood supply to the cardiac muscle in patients with severe coronary artery disease. The study, known as Angiogenesis for the Treatment of Coronary Heart Disease (ACORD), is a randomized, double-blind, placebo-controlled trial that compares the use of a protein at three dose levels with a placebo. The therapy is delivered to the heart muscle by threading a catheter through a small incision in the upper leg. "Other studies have hinted that this approach can reduce the severity of angina in patients who have exhausted all other treatment options," said Oscar Marroquin, M.D., director of the UPMC Center for Interventional Cardiology Research and principal investigator of the study. "It appears the protein, called FGF-1, is able to stimulate the growth of new blood vessels to get around existing blockages and improve blood flow to the heart." This trial is designed to see whether FGF-1 can help patients and, if so, how much should be given. To be eligible for the study, patients must have a history of angina or chronic chest pain that persists despite optimal drug therapy. The ACORD trial is expected to enroll 120 patients, including 10 from the UPMC Cardiovascular Institute, at 30 medical centers throughout the United States. University of Pittsburgh


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009